Foundayo- The New GLP-1 oral option

This month, the FDA approved a brand-new GLP-1 medication for weight loss: Foundayo (orforglipron), developed by Eli Lilly.

This marks an exciting shift in obesity medicine—because for the first time, we now have another oral (pill) option that doesn’t require injections.

How is this different from other GLP-1 medications?

Most GLP-1 medications you’ve heard of—like Wegovy or Zepbound—are injectable.

Even the newer oral version of Wegovy comes with strict instructions:

- Take first thing in the morning 

- On an empty stomach 

- Wait 30 minutes before eating 

That can be hard to stick with long term. So, what makes Foundayo unique?

Foundayo (orforglipron) is a non-peptide GLP-1 receptor agonist. Most GLP-1 medications are peptides, which break down easily in the stomach and require injections or special absorption rules.

 Foundayo is different. Because it’s a small molecule (non-peptide):

- It can be taken with or without food 

- It does not require fasting 

- It’s easier to incorporate into daily life 

How does it work? Like other GLP-1 medications, Foundayo helps with weight loss by:

- Decreasing appetite 

- Reducing “food noise” 

- Slowing gastric emptying 

- Improving blood sugar control 

 The result: you feel full sooner and stay full longer.

How effective is it?

 Clinical trials have shown around 10–12% body weight loss on average.

 Common side effects include:

- Nausea 

- Vomiting 

- Diarrhea 

- Constipation 

 These are usually dose-dependent and improve over time.

What about cost?

 Pricing may be more accessible than injectables, with potentially lower starting costs and more consistent pricing. Current cash pay options are listed on their site

We are entering a new phase of obesity medicine with more options, more flexibility, and more personalized care!

Disclaimer: This content is for educational purposes only and does not constitute medical advice.